Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics.
Read more about cookies
LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib
dec. 2025
Marinda, Meertens, et al
Journal of pharmaceutical and biomedical analysis
Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen
dec. 2025
Lotte M.G., Hulskotte, et al
Cancer chemotherapy and pharmacology
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma
dec. 2025
Marinda, Meertens, et al
Cancer chemotherapy and pharmacology
Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours
sep. 2025
Joris M., van Sabben, et al
Oncology and Therapy
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
